PK MED Appoints Yvonne Bokelman as Chairman of the Board of Directors
July 29 2024 - 3:00AM
Business Wire
PK MED, a French biotech company founded in 2019 by Truffle
Capital, announces the appointment of Yvonne Bokelman as Chairman
of the Board of Directors.
Yvonne has held a number of executive positions in industry,
most recently as Chief Executive Officer of Alyve Medical, a
start-up in the musculoskeletal space. Prior to that she spent more
than a decade with Zimmer Biomet, a world leading orthopedic
company, in a variety of leadership positions, including as
President and General Manager in the last several years, and she
was with Medtronic Spine & Biologics for six years as well.
Early in her career, she worked in hospital administration and
spent several years as Executive Vice President at QuadraMed, a
healthcare IT company. Yvonne has an MBA and is a Fellow in the
American College of Healthcare Executives.
In her career, Yvonne has acquired a unique executive experience
in medical device, hospitals, consulting, and healthcare
information technology. She is an accomplished business operations
executive, market access expert, transformational and strategical
leader, who has been involved in numerous product launches and
commercialization of devices and therapies.
Yvonne Bokelman has a history of commercializing solutions that
help patients treat musculoskeletal pain. Her experience will be
particularly useful in developing PKM-01, an innovative
intra-articular injection for the treatment of gout and pain
relief. This solution for gout, as well as treatments discovered to
tackle other conditions, testify to PK MED's outstanding potential,
which Yvonne Bokelman is delighted to support.
Philippe Pouletty, M.D., founder of PK MED and CEO of Truffle
Capital said: “We are very proud of PK MED’s achievements. It
is now time to welcome new talent with strong industry, market
access and international experience to the Board of Directors of PK
MED, and I am delighted to offer the Chairmanship to Yvonne
Bokelman who has a stellar career in healthcare and the life
sciences industry.”
Yvonne Bokelman, Chairman of the Board of Directors of PK
MED, said: "I’m looking forward to my new role
with the team of PK MED at such a significant time in the company’s
development. PK MED has tremendous potential and I thank the
members of the Board of Directors for their trust.”
About PK MED PK MED is a French biotechnology company,
founded in 2019 by Truffle Capital, developing injectable smart
implants for drug release in rheumatology and cell homing for bone
marrow transplantation. PK MED's unique expertise and technological
know-how enable evolving existing systemic treatments into new,
safer and more effective patented local therapies. PK MED has
developed a portfolio of projects in indications where medical
needs are high, starting with gout (PKM-01) and Hematopoietic Stem
Cells transplants (PKM-02).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729316415/en/
Primatice Armand Rigaudy – armandrigaudy@primatice.com /
07 88 96 41 84